Annoroad and Kerui Biotech Announce Strategic Partnership to Deliver Integrated Solutions for Gene Functional Research

Aug 21, 2018 00:00 CST Updated 00:00

CorreGene

Developer of Tumor Immunotherapy and Gene Therapy Technologies

Annoroad

Genomics Technology Researcher

The purpose of this strategic collaboration is to combine Annoroad’s strengths in high-throughput sequencing services with Beijing Kerui Biological Technology Co., Ltd.’s expertise in gene editing technology. The two parties will engage in in-depth cooperation on the integrated application of epigenomic sequencing, single-cell multi-omics sequencing, and 3D genomics sequencing technologies with gene editing techniques, providing comprehensive solutions for functional studies encompassing gene reading, rewriting, and writing capabilities, thereby serving the broader scientific research community. This partnership fully leverages the complementary advantages of both parties, promoting mutual benefit and win-win outcomes in the fields of scientific research services and precision medicine.

Photos of the Strategic Cooperation Signing Ceremony

About Annoroad

Headquartered in Beijing, Annoroad is a renowned enterprise in the high-throughput sequencing industry. As a subsidiary brand of Annoroad dedicated to scientific research services, AnnoGene leverages robust high-throughput sequencing and high-performance computing platforms to independently develop advanced genomic sequencing services and bioinformatics technologies. It has established a strong Bio-IT foundation and industrialized service capabilities. Currently, AnnoGene engages in extensive scientific collaborations with universities and research institutions both domestically and internationally across multiple omics levels, including genomics, transcriptomics, and epigenetics. Its areas of expertise encompass fundamental research on major human diseases, molecular breeding in plants and animals, genetics and evolution, environmental microbiology, and ecology. The company has developed distinctive advantages in gene expression analysis, single-cell technologies, and chromosome Hi-C technology, thereby providing superior technical solutions for life science research. AnnoGene maintains broad collaborations with prestigious domestic and international research institutes, such as the Institut Curie in France, Peking University, Tsinghua University, Sun Yat-sen University, and the Chinese Academy of Sciences. Related research findings have been published in international journals such as Nature, Science, and Immunity.

About Kerui Bio

Beijing Kerui Biological Technology Co., Ltd. was co-founded by several Peking University alumni and overseas returnees, dedicated to the research and development of anti-tumor immunotherapy technologies as well as the development and service of gene editing products. Through technological innovation, Kerui Biology has established a rapid and efficient SMART-TCR affinity optimization platform, providing therapeutic TCR products for cellular immunotherapy of solid tumors. Meanwhile, Kerui Biology offers more professional and ingenious gene editing products and services to biomedical research institutions, helping customers efficiently implement in vitro and in vivo gene editing to accelerate scientific research progress. The company has established a one-stop gene editing platform that enables various gene editing operations—including gene knockout, gene knock-in, chromosomal sequence editing, site-specific epigenetic editing, reporter gene cell line construction, gene activation and silencing, and high-throughput CRISPR library screening—using vector tools such as lentiviruses and adeno-associated viruses (AAV), along with cell line engineering services. Currently, the company has established close business and R&D collaborations with renowned domestic and international research institutions, including Harvard University, Peking University, Sun Yat-sen University, and the Chinese Academy of Agricultural Sciences. The company has received honors such as "Zhongguancun High-Tech Enterprise" and being ranked among the Top 50 in the Beijing preliminary round of the 2017 "Maker China" Innovation and Entrepreneurship Competition.

We look forward to the collaboration between both parties driving greater achievements in research services and precision medicine, thereby providing convenient and efficient services to the broader scientific research community.